“Health equity” is disappearing from some corporate conversations, but does that mean the work behind it is disappearing too? For pharmaceutical marketers, the answer matters. As DEI-related terminology becomes more politically sensitive, health equity marketing is entering a period in which organizations may change the words they use without changing the communities they serve, the barriers they address, or the outcomes they hope to improve.
Table of Contents
- Why health equity language is changing
- When terminology changes but strategy does not
- What pharma marketers should focus on instead
- Building durable community health partnerships
- Conclusion
- Frequently Asked Questions
Why Health Equity Language Is Changing
A recent example comes from Black Health Matters, a nonprofit focused on preventive health education and access within Black communities.
In September 2026, founder and CEO Roslyn Young-Daniels told MediaPost that the organization no longer uses the phrase “health equity” in proposals seeking pharmaceutical sponsorship. Instead, it has begun using “population health.” According to Young-Daniels, however, the mission remains focused on helping people and improving health outcomes.
The distinction is important for marketers. Words can carry political, organizational, and legal associations that change over time. Consequently, communications teams may adjust terminology to match the environment in which corporate decisions are being made.
Yet a vocabulary change does not automatically mean that audience needs have changed.
Black Health Matters continues to hold community events focused on preventive care, screenings, education, and connections to healthcare services. Recent reporting has also highlighted continued pharmaceutical support for its community health programs.
Therefore, the more useful question for marketers may not be, “Can we still say health equity?” Instead, it may be, “What health problem are we trying to solve, and whom are we trying to reach?”
When Terminology Changes but Strategy Does Not
Effective health equity efforts have never depended on putting a particular phrase on a presentation slide.
At its core, the strategy starts with identifying differences in access, information, diagnosis, treatment, or health outcomes. Marketers can then design communications and partnerships around those differences.
For example, a campaign may need culturally relevant education for a community with low screening rates. Another program might focus on affordability information, transportation barriers, caregiver support, or connections to local providers.
None of those needs disappear when terminology changes.
The FDA Office of Minority Health and Health Equity has also emphasized communication that reaches underserved populations. Its work includes culturally and linguistically tailored health education, as well as research designed to better understand patient perspectives and unmet needs.
That is why marketers should separate strategic purpose from corporate vocabulary.
A company may describe its work as population health, patient engagement, community outreach, health access, or another term. However, teams should still be able to explain the audience being served, the barrier being addressed, and the measurable result the program is designed to achieve.
Ultimately, these community health strategies should be judged by what they accomplish, not simply by what they are called.
What Pharma Marketers Should Focus on Instead
For pharma marketing teams navigating politically sensitive language, clarity of purpose becomes especially important.
First, define the patient need before choosing the terminology. Instead of beginning with a broad corporate label, identify a measurable challenge such as screening gaps, delayed diagnosis, low treatment awareness, affordability barriers, or limited participation in clinical research.
Next, build the audience strategy from evidence rather than assumptions.
Demographic data can help marketers identify patterns, but community insights provide necessary context. Patient organizations, caregivers, healthcare professionals, and local advocates can often explain why a barrier exists and how people actually experience it.
In addition, marketers should evaluate whether their media strategy reaches people where healthcare decisions occur.
A national awareness campaign can generate impressions while still missing communities facing the greatest access barriers. Community partnerships, local events, culturally relevant media, and trusted patient organizations may sometimes deliver deeper engagement.
The same principle applies to patient advocacy. Relationships with patient organizations work best when they become long-term partnerships rather than short-term campaign transactions.
For health equity marketing to remain meaningful, the strategy should stay connected to real patient needs rather than relying on terminology alone.
Building Durable Community Health Partnerships
Changing political environments make durable partnerships even more valuable.
Community organizations often possess something pharmaceutical brands cannot quickly build through traditional marketing: established trust.
They understand local concerns, cultural differences, healthcare access challenges, and the communication channels people already use. Therefore, marketers that involve these organizations early can design programs around real patient behavior instead of generalized audience profiles.
However, partnerships should not become a way to borrow credibility temporarily.
Brands should establish clear goals, appropriate funding, transparent responsibilities, and practical measures of impact. For example, marketers might track screening participation, education completion, referrals, resource utilization, or engagement with patient-support services.
Furthermore, the language used publicly should accurately reflect the work being performed.
Calling a program “population health” rather than “health equity” does not automatically make it more or less meaningful. What matters is whether the initiative addresses a genuine need and whether patients receive useful support.
That distinction could become increasingly important as healthcare organizations reconsider DEI-related language while continuing programs designed for specific populations.
For pharma marketers, adaptability does not require abandoning the strategy. Instead, it requires being precise about why the work exists.
Conclusion
Removing “health equity” from a pitch deck does not necessarily mean the underlying strategy has disappeared. Black Health Matters offers a useful example: its sponsorship language has changed, while its stated mission and community health activities continue.
For pharmaceutical marketers, this moment creates an opportunity to focus less on labels and more on substance. Identify unmet patient needs. Understand barriers. Work with trusted organizations. Measure outcomes. Then use language that accurately describes the work without allowing terminology to become a substitute for strategy.
Political language may continue to shift. Patient needs will remain.
Frequently Asked Questions
What is health equity marketing?
This approach uses audience insights, culturally relevant communication, access information, and community partnerships to address differences in how people receive health information and support.
Is population health the same as health equity?
Not exactly. Population health generally examines health outcomes across groups of people, while health equity focuses more specifically on reducing avoidable differences and barriers. However, individual programs may address similar patient needs under either label.
Why are healthcare organizations changing DEI-related language?
Some organizations are reconsidering terminology because DEI-related language has become more politically and legally sensitive. However, changes in terminology do not necessarily mean that underlying patient programs or community partnerships have ended.
How can pharma marketers support underserved communities?
Marketers can study specific access barriers, partner with trusted community organizations, create culturally relevant education, provide clear information about patient-support resources, and measure whether programs improve meaningful engagement.
Should pharmaceutical brands stop using the term health equity?
The appropriate terminology depends on organizational, legal, regulatory, and communications considerations. Regardless of the label chosen, marketers should clearly define the audience need, program purpose, patient benefit, and measurable outcome.
This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.
